Posts

Reditus ‘on the front lines in the fight against cancer

Reditus Laboratories is excited to bring on our first biomarker as we move to the forefront of malignancy and precision pathology. The test will determine whether patients with certain cancers are good candidates for a specific cancer treatment and soon will be available at Reditus.

Reditus Data Confirm Omicron Quickly Became Dominant Variant

Reditus Laboratories’ data have confirmed what some people already suspected — that the omicron variant quickly became the predominant COVID-19 variant in Illinois.

REDITUS EXPANDING INTO MICROBIOLOGY TESTING

Reditus Laboratories is expanding into microbiology testing to help doctors to determine appropriate antibiotic therapy to fight urinary tract infections (UTIs) and wound infections…

PATHOLOGY LAB TRANSFORMS, RUNS 1M COVID-19 TESTS

Histopathology lab adapts its molecular capabilities to handle ever-greater numbers of SARS-CoV-2 tests By Robert Michel| From The Dark Report Volume XXVIII No. 3 – March 1, 2021 Issue CEO SUMMARY: Last spring, a histopathology lab in Illinois began running molecular COVID-19 tests and decided the clinical side of the lab would focus exclusively on PCR testing […]